Imugene Ltd
ASX:IMU

Watchlist Manager
Imugene Ltd Logo
Imugene Ltd
ASX:IMU
Watchlist
Price: 0.305 AUD Market Closed
Market Cap: 96.2m AUD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of IMU.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IMU Intrinsic Value
Not Available
Base Case Scenario
Compare IMU to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Substantial clinical risk remains with Imugene’s CF33-based oncolytic virus platform, as disappointing trial results for even one major candidate could undermine investor confidence and derail the company’s broader immuno-oncology pipeline.

Heavily reliant on equity issuance and government grants for funding, Imugene may face significant dilution to existing shareholders if clinical timelines stretch and further capital is needed to support late-stage studies.

Growing competition in the immuno-oncology space, particularly from larger pharmaceutical players with far greater resources, could overshadow Imugene’s pipeline and limit licensing or commercialization prospects.

Bull Theses

Imugene’s multivalent approach to immuno-oncology, highlighted by its CF33 oncolytic virus and HER-Vaxx candidates, offers significant potential breakthroughs in treating various tumor types, positioning the firm as a future leader in next-generation cancer therapies.

Early clinical data has shown promising efficacy and safety signals, which could attract additional partnerships or licensing deals with big pharma and expedite the development timeline for lead candidates.

Imugene’s expanding intellectual property portfolio and strategic focus on novel checkpoint inhibitors and therapeutic vaccines provide strong competitive barriers and could create long-term shareholder value if the pipeline succeeds.

Show More Less
How do you feel about IMU?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Imugene Ltd

Current Assets 41.7m
Cash & Short-Term Investments 24m
Receivables 10m
Other Current Assets 7.7m
Non-Current Assets 41.8m
Long-Term Investments 224.9k
PP&E 1.7m
Intangibles 31.7m
Other Non-Current Assets 8.2m
Current Liabilities 22.2m
Accounts Payable 6.8m
Accrued Liabilities 6.4m
Other Current Liabilities 8.9m
Non-Current Liabilities 16.4m
Long-Term Debt 2.8m
Other Non-Current Liabilities 13.6m
Efficiency

Free Cash Flow Analysis
Imugene Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Imugene Ltd

Revenue
0 AUD
Operating Expenses
-77.6m AUD
Operating Income
-77.6m AUD
Other Expenses
8.6m AUD
Net Income
-69m AUD
Fundamental Scores

IMU Profitability Score
Profitability Due Diligence

Imugene Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
Declining ROE
21/100
Profitability
Score

Imugene Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

IMU Solvency Score
Solvency Due Diligence

Imugene Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
58/100
Solvency
Score

Imugene Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMU Price Targets Summary
Imugene Ltd

There are no price targets for IMU.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Imugene Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for IMU is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y